Stamatis Karakonstantis1, Evangelos I Kritsotakis2,3, Achilleas Gikas4. 1. Infectious Diseases Unit, Medical School, University of Crete, Heraklion, Crete, Greece. 2. Laboratory of Biostatistics, School of Medicine, University of Crete, Heraklion, Crete, Greece. 3. Department of Epidemiology and Medical Statistics, School of Health and Related Research, University of Sheffield, Sheffield, UK. 4. Department of Internal Medicine, University Hospital of Heraklion, University of Crete, Heraklion, Crete, Greece.
Abstract
BACKGROUND: The literature on the epidemiology, mortality and treatment of pandrug-resistant (PDR) Gram-negative bacteria (GNB) is scarce, scattered and controversial. OBJECTIVES: To consolidate the relevant literature and identify treatment options for PDR GNB infections. METHODS: A systematic search in MEDLINE, Scopus and clinical trial registries was conducted. Studies reporting PDR clinical isolates were eligible for review if susceptibility testing for all major antimicrobials had been performed. Characteristics and findings of retrieved studies were qualitatively synthesized. RESULTS: Of 81 studies reviewed, 47 (58%) were published in the last 5 years. The reports reflected a worldwide dissemination of PDR GNB in 25 countries in 5 continents. Of 526 PDR isolates reported, Pseudomonas aeruginosa (n=175), Acinetobacter baumannii (n=172) and Klebsiella pneumoniae (n=125) were most common. PDR GNB were typically isolated in ICUs, but several studies demonstrated wider outbreak potential, including dissemination to long-term care facilities and international spread. All-cause mortality was high (range 20%-71%), but appeared to be substantially reduced in studies reporting treatment regimens active in vitro. No controlled trial has been performed to date, but several case reports and series noted successful use of various regimens, predominantly synergistic combinations, and in selected patients increased exposure regimens and newer antibiotics. CONCLUSIONS: PDR GNB are increasingly being reported worldwide and are associated with high mortality. Several treatment regimens have been successfully used, of which synergistic combinations appear to be most promising and often the only available option. More pharmacokinetic/pharmacodynamic and outcome studies are needed to guide the use of synergistic combinations.
BACKGROUND: The literature on the epidemiology, mortality and treatment of pandrug-resistant (PDR) Gram-negative bacteria (GNB) is scarce, scattered and controversial. OBJECTIVES: To consolidate the relevant literature and identify treatment options for PDR GNB infections. METHODS: A systematic search in MEDLINE, Scopus and clinical trial registries was conducted. Studies reporting PDR clinical isolates were eligible for review if susceptibility testing for all major antimicrobials had been performed. Characteristics and findings of retrieved studies were qualitatively synthesized. RESULTS: Of 81 studies reviewed, 47 (58%) were published in the last 5 years. The reports reflected a worldwide dissemination of PDR GNB in 25 countries in 5 continents. Of 526 PDR isolates reported, Pseudomonas aeruginosa (n=175), Acinetobacter baumannii (n=172) and Klebsiella pneumoniae (n=125) were most common. PDR GNB were typically isolated in ICUs, but several studies demonstrated wider outbreak potential, including dissemination to long-term care facilities and international spread. All-cause mortality was high (range 20%-71%), but appeared to be substantially reduced in studies reporting treatment regimens active in vitro. No controlled trial has been performed to date, but several case reports and series noted successful use of various regimens, predominantly synergistic combinations, and in selected patients increased exposure regimens and newer antibiotics. CONCLUSIONS: PDR GNB are increasingly being reported worldwide and are associated with high mortality. Several treatment regimens have been successfully used, of which synergistic combinations appear to be most promising and often the only available option. More pharmacokinetic/pharmacodynamic and outcome studies are needed to guide the use of synergistic combinations.
Authors: Iordanis Kesisoglou; Brianna M Eales; Kimberly R Ledesma; Paul R Merlau; Vincent H Tam; Weiqun Wang; Michael Nikolaou Journal: Comput Chem Eng Date: 2021-09-13 Impact factor: 3.845
Authors: Majed F Alghoribi; Moayad Alqurashi; Liliane Okdah; Bassam Alalwan; Yahya S AlHebaishi; Abdulmajeed Almalki; Maha A Alzayer; Abdulrahman A Alswaji; Michel Doumith; Mazin Barry Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379
Authors: Christian Schütz; Duy-Khiet Ho; Mostafa Mohamed Hamed; Ahmed Saad Abdelsamie; Teresa Röhrig; Christian Herr; Andreas Martin Kany; Katharina Rox; Stefan Schmelz; Lorenz Siebenbürger; Marius Wirth; Carsten Börger; Samir Yahiaoui; Robert Bals; Andrea Scrima; Wulf Blankenfeldt; Justus Constantin Horstmann; Rebekka Christmann; Xabier Murgia; Marcus Koch; Aylin Berwanger; Brigitta Loretz; Anna Katharina Herta Hirsch; Rolf Wolfgang Hartmann; Claus-Michael Lehr; Martin Empting Journal: Adv Sci (Weinh) Date: 2021-03-18 Impact factor: 16.806